Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis

Autores
Gonzalez Polo, Virginia; Pucci Molineris, Melisa Eliana; Cervera, Victorio; Gambaro, Sabrina Eliana; Yantorno, Silvina E.; Descalzi, Valeria; Tiribelli, Claudio; Gondolesi, Gabriel Eduardo; Meier, Dominik
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target.
Consejo Nacional de Investigaciones Científicas y Técnicas
Facultad de Ciencias Médicas
Materia
Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-nd/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/162649
Acceder
id SEDICI_49848d0c2d1ac5f8a797aa0c5314a0a0
oai_identifier_str oai:sedici.unlp.edu.ar:10915/162649
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosisGonzalez Polo, VirginiaPucci Molineris, Melisa ElianaCervera, VictorioGambaro, Sabrina ElianaYantorno, Silvina E.Descalzi, ValeriaTiribelli, ClaudioGondolesi, Gabriel EduardoMeier, DominikCiencias MédicasLiver diseaseILC2Autoimmune hepatitisSteatohepatitisViral hepatitisIntroduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target.Consejo Nacional de Investigaciones Científicas y TécnicasFacultad de Ciencias Médicas2019-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf366-372http://sedici.unlp.edu.ar/handle/10915/162649enginfo:eu-repo/semantics/altIdentifier/issn/1665-2681info:eu-repo/semantics/altIdentifier/doi/10.1016/j.aohep.2018.12.001info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:34:33Zoai:sedici.unlp.edu.ar:10915/162649Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:34:33.307SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
spellingShingle Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
Gonzalez Polo, Virginia
Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
title_short Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_full Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_fullStr Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_full_unstemmed Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_sort Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
dc.creator.none.fl_str_mv Gonzalez Polo, Virginia
Pucci Molineris, Melisa Eliana
Cervera, Victorio
Gambaro, Sabrina Eliana
Yantorno, Silvina E.
Descalzi, Valeria
Tiribelli, Claudio
Gondolesi, Gabriel Eduardo
Meier, Dominik
author Gonzalez Polo, Virginia
author_facet Gonzalez Polo, Virginia
Pucci Molineris, Melisa Eliana
Cervera, Victorio
Gambaro, Sabrina Eliana
Yantorno, Silvina E.
Descalzi, Valeria
Tiribelli, Claudio
Gondolesi, Gabriel Eduardo
Meier, Dominik
author_role author
author2 Pucci Molineris, Melisa Eliana
Cervera, Victorio
Gambaro, Sabrina Eliana
Yantorno, Silvina E.
Descalzi, Valeria
Tiribelli, Claudio
Gondolesi, Gabriel Eduardo
Meier, Dominik
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
topic Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
dc.description.none.fl_txt_mv Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target.
Consejo Nacional de Investigaciones Científicas y Técnicas
Facultad de Ciencias Médicas
description Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target.
publishDate 2019
dc.date.none.fl_str_mv 2019-03-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/162649
url http://sedici.unlp.edu.ar/handle/10915/162649
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1665-2681
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.aohep.2018.12.001
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.format.none.fl_str_mv application/pdf
366-372
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1846064373218410496
score 13.22299

Publicaciones similares